Windtree Therapeutics, Inc.
WINT
$0.8522
$0.00330.39%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -37.65% | 74.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -17.30% | -58.60% | |||
| Operating Income | 17.30% | 58.60% | |||
| Income Before Tax | 190.00% | 74.73% | |||
| Income Tax Expenses | 67.92% | -221.83% | |||
| Earnings from Continuing Operations | 200.65% | 77.14% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 200.65% | 77.14% | |||
| EBIT | 17.30% | 58.60% | |||
| EBITDA | 16.92% | 58.71% | |||
| EPS Basic | 100.19% | 79.78% | |||
| Normalized Basic EPS | 115.07% | 83.23% | |||
| EPS Diluted | 100.19% | 79.78% | |||
| Normalized Diluted EPS | 115.07% | 83.23% | |||
| Average Basic Shares Outstanding | 870.62% | 53.91% | |||
| Average Diluted Shares Outstanding | 870.62% | 53.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 1.89% | -- | |||